Ramon Salazar

Summary

Country: Spain

Publications

  1. ncbi request reprint [Gastrointestinal and pancreatic neuroendocrine tumors]
    Ramon Salazar
    Servicio de Oncologia Medica, Institut Catala d Oncologia, L Hospitalet de Llobregat, Barcelona, Espana
    Med Clin (Barc) 127:227-31. 2006
  2. ncbi request reprint Rare functioning pancreatic endocrine tumors
    Dermot O'Toole
    Department of Gastroenterology, Beaujon Hospital, Clichy, France
    Neuroendocrinology 84:189-95. 2006
  3. ncbi request reprint Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, 08907 s n L Hospitalet de Llobregat, Barcelona, Spain
    Cancer Chemother Pharmacol 72:75-83. 2013
  4. doi request reprint A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Avda Gran Via 199 203, Barcelona, Spain
    Cancer Chemother Pharmacol 70:673-81. 2012
  5. ncbi request reprint Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer
    Ramon Salazar
    Department of Medical Oncology, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Autovía Castelldefels, Barcelona, Spain
    Clin Transl Oncol 14:592-8. 2012
  6. doi request reprint Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer
    Ramon Salazar
    Institut Catal DOncologiaIDIBELL, LHospitalet Barcelona, Barcelona, Spain
    Drugs 71:841-52. 2011
  7. doi request reprint Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Ramon Salazar
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Av Gran Vía 199 203, Barcelona, Spain 08907
    J Clin Oncol 29:17-24. 2011
  8. doi request reprint Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
    Ramon Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, S N, L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Invest New Drugs 29:1406-13. 2011
  9. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
  10. doi request reprint Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype
    Alvaro Aytes
    Translational Research Laboratory, Institut Català d Oncologia Institut d Investigació Biomèdica de Bellvitge IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Carcinog 51:746-53. 2012

Detail Information

Publications34

  1. ncbi request reprint [Gastrointestinal and pancreatic neuroendocrine tumors]
    Ramon Salazar
    Servicio de Oncologia Medica, Institut Catala d Oncologia, L Hospitalet de Llobregat, Barcelona, Espana
    Med Clin (Barc) 127:227-31. 2006
  2. ncbi request reprint Rare functioning pancreatic endocrine tumors
    Dermot O'Toole
    Department of Gastroenterology, Beaujon Hospital, Clichy, France
    Neuroendocrinology 84:189-95. 2006
  3. ncbi request reprint Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, 08907 s n L Hospitalet de Llobregat, Barcelona, Spain
    Cancer Chemother Pharmacol 72:75-83. 2013
    ..This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion...
  4. doi request reprint A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Avda Gran Via 199 203, Barcelona, Spain
    Cancer Chemother Pharmacol 70:673-81. 2012
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin...
  5. ncbi request reprint Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer
    Ramon Salazar
    Department of Medical Oncology, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Autovía Castelldefels, Barcelona, Spain
    Clin Transl Oncol 14:592-8. 2012
    ..A prospective phase II study was conducted to assess the clinical activity and tolerability of oxaliplatin, capecitabine, and radiotherapy (RT) for neoadjuvant therapy of stages II-III rectal cancer...
  6. doi request reprint Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer
    Ramon Salazar
    Institut Catal DOncologiaIDIBELL, LHospitalet Barcelona, Barcelona, Spain
    Drugs 71:841-52. 2011
    ..Results of ongoing trials of dual-targeted therapy combinations will define future therapies for advanced WDNET...
  7. doi request reprint Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Ramon Salazar
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Av Gran Vía 199 203, Barcelona, Spain 08907
    J Clin Oncol 29:17-24. 2011
    ..This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC)...
  8. doi request reprint Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
    Ramon Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, S N, L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Invest New Drugs 29:1406-13. 2011
    ..4 months. In conclusion, plitidepsin 2.4 mg/m(2) and carboplatin AUC = 5 min*mg/ml is a safe dose for future phase II studies evaluating the use of this combination in cancer patients potentially sensitive to platinum-based therapy...
  9. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
    ....
  10. doi request reprint Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype
    Alvaro Aytes
    Translational Research Laboratory, Institut Català d Oncologia Institut d Investigació Biomèdica de Bellvitge IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Carcinog 51:746-53. 2012
    ....
  11. pmc Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death
    Mireia Berdiel-Acer
    Laboratory of Translational Research, Institut Català d Oncologia IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
    Neoplasia 13:931-46. 2011
    ..Therefore, the liver microenvironment induces more efficiently the aggressiveness of colorectal cancer cells than other matched microenvironments do but secondarily evokes cell death. Resistant cells displayed higher stemness capacity...
  12. ncbi request reprint Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function
    Beatriz Pardo
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Med Oncol 29:2240-50. 2012
    ..Stratification criteria based on baseline AP apparently did not segregate the patients according to their liver dysfunction degree. Antitumor activity was found in patients with pretreated ovarian cancer...
  13. doi request reprint Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial
    Josep Tabernero
    Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 19:2541-50. 2013
    ..This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)...
  14. doi request reprint Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Target Oncol 4:287-96. 2009
    ..In this article we aim to review the recent development of the main molecules that target these proteins and have showed promising activity in the treatment of GEPNETs...
  15. doi request reprint Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors
    Beatriz Pardo
    Institut Català d Oncologia and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 14:1116-23. 2008
    ....
  16. doi request reprint A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...
  17. pmc Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer
    Rebeca Sanz-Pamplona
    Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL and CIBERESP, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Cancer 13:46. 2014
    ..The tumor influence in the environment could both promote an anti-tumor or a pro-tumor response...
  18. pmc Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer
    Catia Moutinho
    Affiliations of authors Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain CM, AM C, FJC, ME Medical Oncology Service, Catalan Institute of Oncology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain AM C, EM B, AA Department of Medical Oncology CS, RS and Clinical Informatics Unit VN P, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L Hospitalet de Llobregat, Barcelona, Spain Department of Pathology, Germans Trias i Pujol Foundation, Barcelona, Spain EM Department of Hematology and Oncology, Ospedale Niguarda Ca Granda, Milan, Italy AS B, AC, SS Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain EE, JT Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Barcelona, Spain ME Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain ME
    J Natl Cancer Inst 106:djt322. 2014
    ..A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause...
  19. ncbi request reprint A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours
    Miguel Angel Izquierdo
    Department of Clinical Oncology, IDIBELL, Institut Catala d Oncologia, Hospital Duran i Reynals, Avda Gran Via, S N, Km 2, 7, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Eur J Cancer 42:1789-96. 2006
    ..The pharmacokinetics of PTX are not influenced by DTX but DTX pharmacokinetics depend on the sequence of administration, which influences its haematological toxicity profile...
  20. pmc Gene expression differences between colon and rectum tumors
    Rebeca Sanz-Pamplona
    Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL, and CIBERESP, Barcelona, Spain
    Clin Cancer Res 17:7303-12. 2011
    ..We conducted a molecular study based on gene expression data of tumors from colon and rectum to assess the degree of similarity between these cancer sites at transcriptomic level...
  21. ncbi request reprint A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors
    Margarita Majem
    Institut Catala D Oncologia Duran i Reynals, L Hospitalet de Llobregat, Spain
    J Liposome Res 19:261-6. 2009
    ..The recommended dose is 70 mg/m(2) with prophylactic antihistamines and corticoids to preempt allergic reaction...
  22. doi request reprint Association between habitual dietary flavonoid and lignan intake and colorectal cancer in a Spanish case-control study (the Bellvitge Colorectal Cancer Study)
    Raul Zamora-Ros
    Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Avda Gran Via 199 203, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Cancer Causes Control 24:549-57. 2013
    ..However, current epidemiological evidence for a protective effect of flavonoid intake upon colorectal cancer is promising but not conclusive...
  23. ncbi request reprint Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
    Ramon Salazar
    Clinical Research Unit, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Ctra Gran Vía, 08907 s n, Barcelona, Spain
    Cancer Chemother Pharmacol 73:1205-15. 2014
    ..Pharmacokinetics (PK) and antitumor activity were additionally evaluated...
  24. pmc Polymorphisms in alcohol metabolism genes ADH1B and ALDH2, alcohol consumption and colorectal cancer
    Marta Crous-Bou
    Cancer Prevention and Control Program, Catalan Institute of Oncology, Barcelona, Spain Colorectal Cancer Group, Bellvitge Biomedical Research Institute and Consorcio de Investigación Biomédica de Epidemiología y Salud Pública CIBERESP, Barcelona, Spain
    PLoS ONE 8:e80158. 2013
    ..The aim of this study is to analyze the association between SNPs in ADH1B and ALDH2 genes and CRC risk, and also the main effect of alcohol consumption on CRC risk in the study population...
  25. ncbi request reprint Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma
    Joan Maurel
    Department of Medical Oncology, Hospital Clinic Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Int J Radiat Oncol Biol Phys 62:91-6. 2005
    ..To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer...
  26. pmc PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts
    David G Mollevi
    Translational Research Laboratory, Institut Catala d Oncologia, Institut d Investigació Biomèdica de Bellvitge IDIBELL, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Mol Cancer 8:46. 2009
    ..We demonstrate that products secreted by CAFs trigger PRL-3 overexpression in cancer cells. Identification of these factors may contribute to new stroma-targeted therapies for desmoplastic tumours...
  27. doi request reprint Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer Metastasis Rev 30:27-34. 2011
    ..In this article, we aim to review the recent development of the main molecules that target mTOR complex and have showed promising activity in the treatment of GEPNETs...
  28. ncbi request reprint Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
    Ramon Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Barcelona, Spain
    Invest New Drugs 32:644-52. 2014
    ..In conclusion, no optimal dose was reached due to overlapping myelosuppression despite stratification according to prior treatment. Therefore, this carboplatin plus PM00104 combination was not selected for further clinical research. ..
  29. ncbi request reprint New approaches but the same flaws in the search for prognostic signatures
    Ramon Salazar
    Authors Affiliations Department of Medical Oncology and Translational Research Laboratory, Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, L Hospitalet de Llobregat and Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 20:2019-22. 2014
    ..The approach followed by the authors is original and biologically sound but could be limited by potential biases and other methodologic limitations...
  30. ncbi request reprint The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning
    Rodrigo Dienstmann
    From the Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Medical Oncology, Translational Research Laboratory, Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain
    Am Soc Clin Oncol Educ Book 34:91-9. 2014
    ..We believe that identification of CRC subtypes based on integrative genomic analyses will provide a better guide for patient stratification and for rational design of drugs targeting specific pathways. ..
  31. ncbi request reprint Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  32. doi request reprint Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer
    Sebastiano Biondo
    Department of Surgery, Colorectal Unit, University Hospital of Bellvitge, University of Barcelona, Barcelona, Spain
    Am J Surg 195:427-32. 2008
    ..The aim of this observational study was to analyze the differences between patients with obstructive and perforated colonic cancer who managed with emergency curative surgery...
  33. doi request reprint Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
    ..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...